Trials / Suspended
SuspendedNCT03325322
Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease
Frailty, Inflammation, and Stem Cell Functionality in Chronic Kidney Disease
- Status
- Suspended
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The proposed studies will examine the effect of fisetin on adipose tissue-derived mesenchymal stem/stromal cell function, kidney function, markers of inflammation, and physical function in individuals with advanced chronic kidney disease.
Detailed description
The proposed studies will examine the effect of fisetin on adipose tissue-derived mesenchymal stem/stromal cell function, kidney function, markers of inflammation, and physical function in individuals with advanced chronic kidney disease, particularly diabetic kidney disease. This study will involve a single 2-day oral treatment regimen with fisetin or placebo. Study subjects will be randomized 2:1 to study drug or placebo. Study visits will consist of blood, urine, and abdominal wall skin and subcutaneous fat samplings in addition to testing of physical strength at given time points. Subjects will be followed for a total of 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Fisetin | Flavonoid family |
| DRUG | Placebo oral capsule | Placebo |
Timeline
- Start date
- 2018-01-02
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
- First posted
- 2017-10-30
- Last updated
- 2026-01-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03325322. Inclusion in this directory is not an endorsement.